JP2013525305A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525305A5
JP2013525305A5 JP2013505156A JP2013505156A JP2013525305A5 JP 2013525305 A5 JP2013525305 A5 JP 2013525305A5 JP 2013505156 A JP2013505156 A JP 2013505156A JP 2013505156 A JP2013505156 A JP 2013505156A JP 2013525305 A5 JP2013525305 A5 JP 2013525305A5
Authority
JP
Japan
Prior art keywords
antigen
multimeric ligand
subject
region
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013505156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525305A (ja
JP5975983B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/032572 external-priority patent/WO2011130566A2/en
Publication of JP2013525305A publication Critical patent/JP2013525305A/ja
Publication of JP2013525305A5 publication Critical patent/JP2013525305A5/ja
Application granted granted Critical
Publication of JP5975983B2 publication Critical patent/JP5975983B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013505156A 2010-04-16 2011-04-14 固形腫瘍を処置するための方法 Active JP5975983B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32512710P 2010-04-16 2010-04-16
US61/325,127 2010-04-16
US35176010P 2010-06-04 2010-06-04
US61/351,760 2010-06-04
US201161442582P 2011-02-14 2011-02-14
US61/442,582 2011-02-14
PCT/US2011/032572 WO2011130566A2 (en) 2010-04-16 2011-04-14 Method for treating solid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016060361A Division JP2016117770A (ja) 2010-04-16 2016-03-24 固形腫瘍を処置するための方法

Publications (3)

Publication Number Publication Date
JP2013525305A JP2013525305A (ja) 2013-06-20
JP2013525305A5 true JP2013525305A5 (enExample) 2014-05-01
JP5975983B2 JP5975983B2 (ja) 2016-08-23

Family

ID=44799326

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013505156A Active JP5975983B2 (ja) 2010-04-16 2011-04-14 固形腫瘍を処置するための方法
JP2016060361A Withdrawn JP2016117770A (ja) 2010-04-16 2016-03-24 固形腫瘍を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016060361A Withdrawn JP2016117770A (ja) 2010-04-16 2016-03-24 固形腫瘍を処置するための方法

Country Status (6)

Country Link
US (2) US20110287038A1 (enExample)
EP (1) EP2558109A4 (enExample)
JP (2) JP5975983B2 (enExample)
AU (1) AU2011239569B2 (enExample)
CA (1) CA2795947A1 (enExample)
WO (1) WO2011130566A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2557164A1 (en) 2003-02-18 2013-02-13 Kevin M. Slawin Induced activation in dendritic cells
AU2007310946B2 (en) * 2006-10-19 2014-06-05 Baylor College Of Medicine Generating an immune response by inducing CD40 and pattern recognition receptors
DK2331680T3 (en) 2008-09-22 2017-08-21 Baylor College Medicine Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters
KR101712231B1 (ko) 2009-10-29 2017-03-03 아벤티스 파마 소시에떼아노님 카바지탁셀의 신규한 항종양 용도
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US20130143237A1 (en) * 2011-11-29 2013-06-06 Genentech, Inc. Compositions and methods for prostate cancer analysis
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
AU2014236726A1 (en) 2013-03-14 2015-09-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
WO2014144731A2 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same
MX369709B (es) * 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
JP6493692B2 (ja) 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
JP6467406B2 (ja) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
JP6496472B2 (ja) * 2013-07-03 2019-04-03 三菱重工機械システム株式会社 車載器、及びスプーフィング検知方法
JP6772063B2 (ja) * 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
EP2940136A1 (en) * 2014-04-30 2015-11-04 QIAGEN GmbH Method for isolating poly(A) nucleic acids
WO2016036746A1 (en) * 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
US10189880B2 (en) 2014-11-03 2019-01-29 Leiden University Medical Center T cell receptors directed against Bob1 and uses thereof
US10975137B2 (en) * 2014-11-06 2021-04-13 University Of Maryland, Baltimore CD8a and t cell receptor variants and methods of using same in modulating immune cell responses
EP3608408A1 (en) * 2014-12-15 2020-02-12 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US20190008897A1 (en) * 2015-07-22 2019-01-10 University Of Washington Compositions and methods for producing pro-inflammatory macrophages
US11034749B2 (en) 2015-07-28 2021-06-15 The Trustees Of The University Of Pennsylvania Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
JP7171433B2 (ja) * 2015-10-30 2022-11-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法
JP6904667B2 (ja) 2016-06-14 2021-07-21 日本光電工業株式会社 バイトブロック及びガスセンサキット
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
EP3621988A1 (en) 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
WO2019045791A1 (en) * 2017-08-28 2019-03-07 Board Of Trustees Of Michigan State University COMPOSITIONS AND METHODS FOR TREATING CANCER AND INFECTIONS USING BACTERIOPHAGE AND ITS MUTANTS
US12570711B2 (en) 2017-09-27 2026-03-10 Angeles Therapeutics, Inc. Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
EP3720479A2 (en) 2017-12-08 2020-10-14 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining car-t cell efficacy
US20200308144A1 (en) 2017-12-20 2020-10-01 Bellicum Pharmaceuticals, Inc. Multimeric piperidine derivatives
AU2019384145A1 (en) * 2018-11-20 2021-06-10 Innovative Cellular Therapeutics Holdings, Ltd. Modified cell expressing therapeutic agent and uses thereof
CN114981409A (zh) 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
KR20220143642A (ko) * 2019-12-11 2022-10-25 마이얼로이드 테라퓨틱스, 인크. 치료 세포 조성물 및 그의 제조 방법 및 용도
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
AU2021205502A1 (en) * 2020-01-10 2022-07-21 Coimmune, Inc. Methods of treating tumors
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
WO2021248061A1 (en) 2020-06-04 2021-12-09 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
IL299508A (en) 2020-07-01 2023-02-01 Ars Pharmaceuticals Inc Anti-asgr1 antibody conjugates and uses thereof
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
CA3212398A1 (en) 2021-03-17 2022-09-22 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
CA3218780A1 (en) 2021-05-11 2022-11-17 Daniel Getts Methods and compositions for genomic integration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2557164A1 (en) * 2003-02-18 2013-02-13 Kevin M. Slawin Induced activation in dendritic cells
ES2340038T3 (es) * 2003-11-14 2010-05-28 Genvec, Inc. Composicion farmaceutica para tratar cancer de pancreas localmente avanzado (cpla) no extirpable.
AU2007310946B2 (en) * 2006-10-19 2014-06-05 Baylor College Of Medicine Generating an immune response by inducing CD40 and pattern recognition receptors
EP2224954B1 (en) * 2007-11-07 2014-01-08 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
US8114968B2 (en) * 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
WO2009151503A2 (en) * 2008-04-10 2009-12-17 University Of Florida Research Foundation, Inc. Compositions and methods for the treatment of a neoplasia
DK2331680T3 (en) * 2008-09-22 2017-08-21 Baylor College Medicine Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters

Similar Documents

Publication Publication Date Title
JP2013525305A5 (enExample)
Alnefaie et al. Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions
EP3368689B1 (en) Composition for modulating immune responses by use of immune cell gene signature
Brunell et al. Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities
CN112055695A (zh) 用于基因表达的纳米粒子和其用途
CN115297868B (zh) 用于编码核糖核酸的器官保护性表达和调节的组合物及方法
WO2017075465A1 (en) Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
US11788093B2 (en) Chimeric antigen receptor t-cells expressing interleukin-8 receptor
KR102741572B1 (ko) 조직에서 코딩 리보핵산의 표적화된 전달, 발현 및 조절을 위한 조성물 및 방법
Wang et al. Different evasion strategies in multiple myeloma
JP2022546282A (ja) Ｇｏｌｄ制御導入遺伝子による併用療法
Lee et al. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models
Walters et al. Modulating expression of inhibitory and stimulatory immune ‘checkpoints’ using nanoparticulate-assisted nucleic acid delivery
KR20220092543A (ko) 암의 치료를 위한 의약, 조합 의약, 의약 조성물, 면역 응답성 세포, 핵산 전달 비히클 및 제품
Snyder et al. Good CARMA: Turning bad tumor‐resident myeloid cells good with chimeric antigen receptor macrophages
Huang et al. Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer
CN107427581A (zh) T细胞群的改变方法
AU2024236982A1 (en) Mutants of a ligand-dependent corepressor (lcor) and uses thereof
Carreira et al. Nanomedicines as multifunctional modulators of melanoma immune microenvironment
US20240218019A1 (en) Methods and compositions comprising mhc class i peptides
Aljabali et al. The dual promise of oncolytic viruses: selective targeting and therapeutic enhancement in cancer treatment
Mokhtari et al. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers. 2021; 13: 3596
CN113929767A (zh) 具有高亲和力的t细胞受体及其用途
EP4711380A1 (en) Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy
Yuan et al. CD8+ T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA